Early high efficacy as the key to improving prognosis

Pediatric multiple sclerosis (POMS) is a rare but particularly challenging form of the disease. Children and adolescents with MS often experience more relapses, a greater lesion burden on MRI and early-onset cognitive impairment. At the same time, their long-term course is characterized by a delayed but ultimately unstoppable accumulation of disability. For a long time, therapeutic care was limited and restricted to low to moderately effective therapies. In recent years, however, there has been a paradigm shift: highly effective therapies (HETs) are increasingly being used in pediatric patients – with clear benefits for relapse rate, MRI activity and disease progression.